10.6084/m9.figshare.5346181.v1
Mukai H.
Mukai
H.
Hagiwara Y.
Hagiwara
Y.
Imi K.
Imi
K.
Isaka H.
Isaka
H.
Watanabe K.
Watanabe
K.
Matsuyama Y.
Matsuyama
Y.
for the SELECT BC Study Group
for the SELECT BC Study
Group
Supplementary Material for: The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer
Karger Publishers
2017
SELECT BC study
First-line chemotherapy
Second-line chemotherapy
Inverse probability weighting estimation
2017-08-25 11:42:34
Dataset
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_The_Impact_of_Treatment_Preferences_in_Second-Line_Chemotherapy_on_the_Prognosis_of_HER2-Negative_Metastatic_Breast_Cancer/5346181
<i>Objective:</i> We assessed the impact of treatment preferences in second-line chemotherapy on breast cancer prognosis using the SELECT BC study. <i>Methods:</i> The SELECT BC study was performed in patients with HER2-negative metastatic breast cancer treated with initial chemotherapy. From these patients, 618 were assigned to 2 groups (S-1 group, 309; taxane group, 309). The S-1 and taxane groups were each subdivided into 3 groups: crossover group, protocol-recommended group, and other group, and the analysis of overall survival (OS) was performed using Cox regression with inverse probability weighting, to adjust for postrandomization confounding. <i>Results:</i> In the taxane group, the OS of the crossover group (39.6 months) was better than that of the protocol-recommended group (35.7 months) and the other chemotherapy group (36.9 months) (vs. the protocol-recommended group, HR 0.72 [95% CI 0.52-0.98], <i>p </i>= 0.037; vs. the other chemotherapy group, HR 0.71 [95% CI 0.43-1.18], <i>p = </i>0.183). In the S-1 group, there was no statistically significant difference in OS between the 3 groups. <i>Conclusion:</i> The study of the combination of first-line chemotherapy and second-line chemotherapy showed that S-1 might be recommended as a second-line chemotherapy in patients in whom taxane was the primary chemotherapy.